» Articles » PMID: 24012784

Atypical and Classical Forms of the Disease-associated State of the Prion Protein Exhibit Distinct Neuronal Tropism, Deposition Patterns, and Lesion Profiles

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 2013 Sep 10
PMID 24012784
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

A number of disease-associated PrP forms characterized by abnormally short proteinase K-resistant fragments (atypical PrPres) were recently described in prion diseases. The relationship between atypical PrPres and PrP(Sc), and their role in etiology of prion diseases, remains unknown. We examined the relationship between PrP(Sc) and atypical PrPres, a form characterized by short C-terminal proteinase K-resistant fragments, in a prion strain of synthetic origin. We found that the two forms exhibit distinct neuronal tropism, deposition patterns, and degree of pathological lesions. Immunostaining of brain regions demonstrated a partial overlap in anatomic involvement of the two forms and revealed the sites of their selective deposition. The experiments on amplification in vitro suggested that distinct neuronal tropism is attributed to differences in replication requirements, such as preferences for different cellular cofactors and PrP(C) glycoforms. Remarkably, deposition of atypical PrPres alone was not associated with notable pathological lesions, suggesting that it was not neurotoxic, but yet transmissible. Unlike PrP(Sc), atypical PrPres did not show significant perineuronal, vascular, or perivascular immunoreactivity. However, both forms showed substantial synaptic immunoreactivity. Considering that atypical PrPres is not associated with substantial lesions, this result suggests that not all synaptic disease-related PrP states are neurotoxic. The current work provides important new insight into our understanding of the structure-pathogenicity relationships of transmissible PrP states.

Citing Articles

Propagation of PrP in mice reveals impact of aggregate composition on prion disease pathogenesis.

Chang S, Hannaoui S, Arifin M, Huang Y, Tang X, Wille H Commun Biol. 2023; 6(1):1162.

PMID: 37964018 PMC: 10645910. DOI: 10.1038/s42003-023-05541-3.


Role of sialylation of N-linked glycans in prion pathogenesis.

Makarava N, Baskakov I Cell Tissue Res. 2022; 392(1):201-214.

PMID: 35088180 PMC: 9329487. DOI: 10.1007/s00441-022-03584-2.


Differential Accumulation of Misfolded Prion Strains in Natural Hosts of Prion Diseases.

Lambert Z, Greenlee J, Cassmann E, Greenlee M Viruses. 2021; 13(12).

PMID: 34960722 PMC: 8706046. DOI: 10.3390/v13122453.


On the reactive states of astrocytes in prion diseases.

Baskakov I Prion. 2021; 15(1):87-93.

PMID: 34057026 PMC: 8168552. DOI: 10.1080/19336896.2021.1930852.


Non-cell autonomous astrocyte-mediated neuronal toxicity in prion diseases.

Kushwaha R, Sinha A, Makarava N, Molesworth K, Baskakov I Acta Neuropathol Commun. 2021; 9(1):22.

PMID: 33546775 PMC: 7866439. DOI: 10.1186/s40478-021-01123-8.


References
1.
Makarava N, Kovacs G, Savtchenko R, Alexeeva I, Ostapchenko V, Budka H . A new mechanism for transmissible prion diseases. J Neurosci. 2012; 32(21):7345-55. PMC: 3368278. DOI: 10.1523/JNEUROSCI.6351-11.2012. View

2.
Makarava N, Kovacs G, Savtchenko R, Alexeeva I, Budka H, Rohwer R . Stabilization of a prion strain of synthetic origin requires multiple serial passages. J Biol Chem. 2012; 287(36):30205-14. PMC: 3436274. DOI: 10.1074/jbc.M112.392985. View

3.
Prusiner S . Prions. Proc Natl Acad Sci U S A. 1998; 95(23):13363-83. PMC: 33918. DOI: 10.1073/pnas.95.23.13363. View

4.
Ghaemmaghami S, Colby D, Nguyen H, Hayashi S, Oehler A, DeArmond S . Convergent replication of mouse synthetic prion strains. Am J Pathol. 2013; 182(3):866-74. PMC: 3586687. DOI: 10.1016/j.ajpath.2012.11.038. View

5.
Piccardo P, Manson J, King D, Ghetti B, Barron R . Accumulation of prion protein in the brain that is not associated with transmissible disease. Proc Natl Acad Sci U S A. 2007; 104(11):4712-7. PMC: 1838665. DOI: 10.1073/pnas.0609241104. View